Skip to main content
OpenTrials

Clinical trial condition

Multiple Myeloma

Explore clinical trials studying Multiple Myeloma. Study availability and eligibility vary by location and protocol.

2,604 public trials 495 recruiting studies
Refine in advanced search Browse all conditions

Multiple Myeloma trial results

Active, Not Recruiting

P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma

NCT04960579

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • City of Hope Goodyear, Arizona, United States
  • University of California San Diego San Diego, California, United States
  • University of California San Francisco San Francisco, California, United States
  • Emory University Atlanta, Georgia, United States
View all 23 locations
View Trial Details
Active, Not Recruiting

Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

NCT06868667

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • GSK Investigational Site Aomori, Japan
  • GSK Investigational Site Fukuoka, Japan
  • GSK Investigational Site Himeji, Japan
  • GSK Investigational Site Kamakura, Japan
View all 16 locations
View Trial Details
Active, Not Recruiting

Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

NCT04246047

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • GSK Investigational Site Yuma, Arizona, United States
  • GSK Investigational Site Denver, Colorado, United States
  • GSK Investigational Site Kansas City, Kansas, United States
  • GSK Investigational Site Fairfield, Ohio, United States
View all 69 locations
View Trial Details
Active, Not Recruiting

China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

NCT06868654

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • GSK Investigational Site Beijing, China
  • GSK Investigational Site Changchun, China
  • GSK Investigational Site Guangzhou, China
  • GSK Investigational Site Hangzhou, China
View Trial Details
Active, Not Recruiting

Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease

NCT04166565

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Extramedullary Plasmacytoma, +13 more
Locations
  • University of Athens Athens, Greece
  • Anticancer Hospital of Thessaloniki Thessaloniki, Greece
  • University of Bologna Bologna, Italy
  • Univerity of Turin Torino, Italy
View Trial Details
Active, Not Recruiting

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

NCT05317416

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Banner Gateway Medical Center Gilbert, Arizona, United States
  • Banner Gateway Medical Pavilion Gilbert, Arizona, United States
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • Ronald Reagan UCLA Medical Center Los Angeles, California, United States
View all 209 locations
View Trial Details

Related conditions